Skip to main content
Premium Trial:

Request an Annual Quote

Affy Shares Slump 8.6 Percent on Lower Revenue Outlook; Bank Downgrades Stock

NEW YORK, Jan. 6 (GenomeWeb News) - Shares in Affymetrix were down 8.6 percent, or $4.04, at $42.86 in mid-afternoon trading after the company cut its fourth-quarter and certain full-year 2005 revenue projections for the second time.

 

As reported by GenomeWeb News this morning, Affymetrix lowered its fourth-quarter revenue projections by 12.5 percent and 2005 product sales projections another 4 percent. The company called the adjustments "growing pains."

 

Citing the company's weak revenues, investment bank Caris & Company downgraded Affymetrix stock to 'Above Average' from 'Buy' today.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.